APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia

ApoC-III is a protein produced in the liver and intestine and enriched in triglyceride-rich lipoproteins (TRLs), including chylomicrons.1, 2 ApoC-III increases plasma triglyceride levels primarily by inhibiting lipoprotein lipase activity and slowing hepatic uptake of triglyceride-rich lipoproteins (TRLs). Hypertriglyceridemia is associated with non-alcoholic fatty liver disease (NAFLD).3 However, there are no approved therapies to treat NAFLD and it is unclear whether triglyceride lowering, particularly with drugs capable of reducing plasma levels by>70%, affects pre-existing hepatic steatosis in patients with severe hypertriglyceridemia (SHTG).

Source: Journal of Clinical Lipidology - April 26, 2023 Category: Lipidology Authors: Thomas A. Prohaska, Veronica J. Alexander, Ewa Karwatowska-Prokopczuk, Joseph Tami, Shuting Xia, Joseph L. Witztum, Sotirios Tsimikas Tags: Brief Communication Source Type: research